ОКОННЕЛЛ Кевин А. (US),РАМАЧАНДРА Рангаппа Нараяна (US),ГОНТ Стефен Дэвид (US),КОРСТВЕТ Ричард Е. (US),УЕСМОЕН Терри Ли (US)
申请号：
RU2013104173/10
公开号：
RU2013104173A
申请日:
2011.06.29
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A vaccine composition comprising an effective immunizing amount of an inactivated antigen from E. canis, wherein said antigen elicits a protective immune response, but it causes a minimal humoral response in a patient, when said vaccine is administered as a primary vaktsiny.2. A vaccine composition according to Claim. 1, wherein said antigen is derived from E. canis, subcultured on sobaki.3 cells. A vaccine composition according to claim. 2, wherein said dog cells are bone marrow cells sobaki.4. A vaccine composition according to claim. 2, wherein said cells have a dog in accession number ATCC No. PTA-10545.5. A vaccine composition according to claim. 4, wherein said antigen is inactivated formalinom.6. The vaccine composition of claim. 5, wherein said vaccine composition additionally comprises a lipophilic adyuvant.7. A vaccine composition according to claim. 6, wherein said adjuvant comprises 6,6-dimikolyat tregalozy.8. A vaccine composition according to claim. 6, wherein the non-polar solvent comprises a lipophilic adjuvant and vaktsinu.9. A vaccine composition according to claim. 8, wherein a nonpolar solvent is chloroform rastvoriteley.10 system. A vaccine composition according to claim. 9, wherein said chloroform solvent system comprises about 65-95% chloroform volume / obem.11. The vaccine composition of claim. 10 wherein said chloroform solvent system comprises about 5.0 to 30 volume% methanol / obem.12. The vaccine composition of claim 11, wherein said chloroform solvent system comprises about 90% chloroform:. 10% methanol: 1.0% water volume / volume sootvetstvenno.13. A vaccine composition comprising (a) formalin-inactivated cell-assoc1. Вакцинная композиция, содержащая эффективное иммунизирующее количество инактивированного антигена из E. canis, где указанный антиген вызывает защитный иммунный ответ, но при этом вызывает минимальный гуморальный ответ у пациента, когда указанную вакцину вводят в качестве первичной вакцины.2. Вакцинная композиция по п. 1
